Alacrita was asked to assess a novel mAB-based approach to suppressing cancer metastases. The client, a biotech incubator with rights to the project, was considering further investment, but needed a third party expert view of the strength of the technology and its prospects in the competitive arena.


Together with an experienced translational oncologist, Alacrita reviewed publications and the lates data from the research group that had invented the approach. We set the analysis in the background of previous and current anti-metastasis projects and concluded that although the development mAb had biological activity, the current dataset was not competitive against the state-of-the art disclosed in the literature. We suggested approaches to reinforcing the evidence base and reviewed our conclusions and recommendations with the client and the PI of the research group. We established a high degree of consensus and were subsequently invited to assess a different project on behalf of the same client.

Research & IP Evaluation Services

Our life science intellectual property practice provides analysis, assessment and strategic advice on life science IP. The practice is focused on both helping clients extract maximum value from their IP portfolios and supporting companies and investors conducting IP due diligence.


Additional Case Studies